JP2012532093A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532093A5
JP2012532093A5 JP2012516867A JP2012516867A JP2012532093A5 JP 2012532093 A5 JP2012532093 A5 JP 2012532093A5 JP 2012516867 A JP2012516867 A JP 2012516867A JP 2012516867 A JP2012516867 A JP 2012516867A JP 2012532093 A5 JP2012532093 A5 JP 2012532093A5
Authority
JP
Japan
Prior art keywords
cbd
therapeutic agent
present
agent according
thcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516867A
Other languages
English (en)
Japanese (ja)
Other versions
JP5904938B2 (ja
JP2012532093A (ja
Filing date
Publication date
Priority claimed from GB0911580A external-priority patent/GB2471523A/en
Application filed filed Critical
Publication of JP2012532093A publication Critical patent/JP2012532093A/ja
Publication of JP2012532093A5 publication Critical patent/JP2012532093A5/ja
Application granted granted Critical
Publication of JP5904938B2 publication Critical patent/JP5904938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516867A 2009-07-03 2010-06-29 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用 Active JP5904938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0911580.9 2009-07-03
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016050485A Division JP2016166205A (ja) 2009-07-03 2016-03-15 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用

Publications (3)

Publication Number Publication Date
JP2012532093A JP2012532093A (ja) 2012-12-13
JP2012532093A5 true JP2012532093A5 (OSRAM) 2013-08-08
JP5904938B2 JP5904938B2 (ja) 2016-04-20

Family

ID=41008705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012516867A Active JP5904938B2 (ja) 2009-07-03 2010-06-29 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用
JP2016050485A Pending JP2016166205A (ja) 2009-07-03 2016-03-15 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016050485A Pending JP2016166205A (ja) 2009-07-03 2016-03-15 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用

Country Status (28)

Country Link
US (4) US9066920B2 (OSRAM)
EP (3) EP2727626A1 (OSRAM)
JP (2) JP5904938B2 (OSRAM)
KR (1) KR101727000B1 (OSRAM)
CN (2) CN106236744A (OSRAM)
AR (1) AR077448A1 (OSRAM)
AU (1) AU2010267775C1 (OSRAM)
BR (1) BR112012000076A2 (OSRAM)
CA (2) CA2766082C (OSRAM)
CY (1) CY1115338T1 (OSRAM)
DK (1) DK2448637T4 (OSRAM)
ES (1) ES2460623T5 (OSRAM)
GB (3) GB2471523A (OSRAM)
HR (1) HRP20140398T4 (OSRAM)
IL (1) IL217280B (OSRAM)
IN (1) IN2012DN00804A (OSRAM)
MX (1) MX2012000257A (OSRAM)
MY (1) MY156759A (OSRAM)
NZ (2) NZ597704A (OSRAM)
PL (1) PL2448637T5 (OSRAM)
PT (1) PT2448637E (OSRAM)
RU (1) RU2563143C2 (OSRAM)
SG (1) SG176914A1 (OSRAM)
SI (1) SI2448637T2 (OSRAM)
TW (1) TWI461191B (OSRAM)
UA (1) UA108852C2 (OSRAM)
WO (1) WO2011001169A1 (OSRAM)
ZA (1) ZA201200373B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016176279A1 (en) * 2015-04-28 2016-11-03 The Regents Of The University Of California Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
EP4031119B1 (en) * 2019-09-17 2025-12-17 Harmony Biosciences Management, Inc. Transdermal treatment of behavioral impairment in developmental and epileptic encephalopathy with cbd
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
CA3187303A1 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
EP4376893A2 (en) 2021-07-29 2024-06-05 Emory University Phosphate prodrugs of cannabinoids
EP4507689A1 (en) 2022-04-12 2025-02-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CZ306277B6 (cs) * 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
DK2314284T3 (en) 2002-08-14 2017-05-22 Gw Pharma Ltd LIQUID CANNABINOID FORMULAS FOR MUSHROAD ADMINISTRATION
CA2994322A1 (en) 2002-08-14 2004-02-14 Gw Pharma Limited Botanical drug substances comprising various proportions of thc and cbd
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
DK2280687T3 (da) 2008-03-26 2019-05-27 Stichting Sanammad Tyggegummisammensætninger omfattende cannabinoider
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
CA2847235C (en) 2011-08-26 2020-07-07 Bial - Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
AU2015266897B2 (en) 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Similar Documents

Publication Publication Date Title
JP2012532093A5 (OSRAM)
RU2012103603A (ru) Применение одного или комбинации фитоканнабиноидов для лечения эпилепсии
MA38276B1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CR11723A (es) Agente para tratar enfermedad
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
PH12012501389A1 (en) Hedgehog inhibitors
MY160377A (en) Topical pharmaceutical compositions
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR TREATING PRESENTATIONS
JP2011504921A5 (OSRAM)
JP2015500340A5 (OSRAM)
RU2016127361A (ru) Гастроретентивные фармацевтические композиции для перорального введения
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
WO2011151786A3 (en) Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
ZA201008022B (en) Pharmaceutical compositions for the treatment of warts
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
PH22011000655U1 (en) Pharmaceutical herbal composition